Companies: 10,795·Total market cap: $144.5T
Evelo Biosciences, Inc.

Evelo Biosciences, Inc.

EVLOOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$1898
P/E Ratio
52W High$0.0006
52W Low$0.0001
Overview

Evelo Biosciences, Inc. (EVLO) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001694665 · EVLO · OTC · as of Jun 9, 2026

Filing snapshot

369
Total Filings
EFFECT
Latest Form
2024-03-08
Most Recent
2018
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001694665 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2023-03-16
Fiscal Year End
Mar 16, 2023
Accession No.
0001694665-23-000024
Primary Document
evlo-20221231.htm
Source: data.sec.gov · CIK 0001694665 · Accession 0001694665-23-000024

Latest Key Filings

10-QQuarterly Report
10-Q
2023-11-09
8-KCurrent Report
8-K
2024-01-26Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
EFFECTEFFECT
EFFECT
2024-03-08
View
15-12G15-12G
15-12G
2024-01-26
View
S-8 POSS-8 POS
S-8 POS
2024-01-26
View
S-8 POSS-8 POS
S-8 POS
2024-01-26
View
POS AMPOS AM
POS AM
2024-01-26
View
8-KCurrent Report
8-K
2024-01-26
View
25-NSE25-NSE
25-NSE
2023-12-27
View
DEFA14AProxy Statement (Additional)
DEFA14A
2023-12-12
View
DEF 14AProxy Statement
DEF 14A
2023-12-12
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2023-12-11
View
8-KCurrent Report
8-K
2023-12-04
View
PRE 14APRE 14A
PRE 14A
2023-12-01
View
8-KCurrent Report
8-K
2023-11-21
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2023-11-13
View
10-QQuarterly Report
10-Q
2023-11-09
View
Showing 1–15 of 232 filingsForm 4 / 144 hidden· 369 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001694665  |  Exchange: OTC · Healthcare

Evelo Biosciences, Inc. (OTC: EVLO) has submitted 369 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2018. As a Healthcare sector company with CIK 0001694665, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Evelo Biosciences, Inc.'s most comprehensive regulatory disclosure. The most recent Evelo Biosciences, Inc. 10-K was filed on 2023-03-16 for fiscal year ending 2023. Historical EVLO 10-K annual reports are available from 2017 through 2023.

Investors researching Evelo Biosciences, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

EVLO SEC Filings · 8 questions

Evelo Biosciences, Inc. (EVLO) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 369 filings and access original documents at no cost. Evelo Biosciences, Inc.'s CIK is 0001694665.

EVLO SEC filingsEvelo Biosciences, Inc. SEC documentsfind EVLO 10-K